CorVel Corporation — Form 10-Q Summary
Reporting period: The filing covers the quarter and nine months ended December 31, 2013, with comparisons to the same periods in 2012. The request metadata says “2012 Q3,” which does not match the filing period.
Business context and results
CorVel provides managed-care and medical cost-containment services, principally to workers’ compensation and auto-insurance payors. Its services include patient management and network solutions. The company reports one operating segment.
| Metric | Three months ended Dec. 31, 2013 | Change year over year | Nine months ended Dec. 31, 2013 | Change year over year |
|---|---|---|---|---|
| Revenue | $121.1 million | +12.9% | $358.6 million | +13.0% |
| Gross profit / gross margin | $27.7 million / 22.9% | +$6.0 million / +2.6 percentage points | $81.9 million / 22.9% | +$14.2 million / +1.6 percentage points |
| Income before tax / margin | $14.5 million / 12.0% | +44.7% | $43.7 million / 12.2% | +37.0% |
| Net income | $8.8 million | +48.1% | $26.1 million | +36.1% |
| Diluted EPS | $0.41 | Up from $0.26 | $1.22 | Up from $0.84 |
Cash flow, liquidity and capital
- Nine-month operating cash flow was $45.6 million, versus $43.6 million a year earlier. Capital expenditures were $12.7 million, compared with $9.2 million; management attributed the increase primarily to construction of a new data center.
- Cash and cash equivalents were $32.7 million at December 31, 2013, up from $19.8 million at March 31, 2013. Working capital was $45.4 million, up from $40.1 million.
- The company reported no debt outstanding. Its revolving credit facility provides up to $10 million and expires in September 2014. An $8.0 million amount of letters of credit is issued separately and does not reduce borrowing availability.
- Nine-month treasury-stock purchases used $24.0 million. The company repurchased 763,168 shares during the nine months and 105,553 shares during the quarter. It reported 1,919,698 shares remaining under the repurchase authorization at quarter-end.
- Contractual obligations totaled $42.9 million, including $39.5 million of operating leases and $2.3 million for software licenses. Current liabilities were $65.7 million and total assets were $202.9 million at December 31.
Changes, outlook and risks
- Quarterly revenue growth was attributed to higher patient-management and network-solutions activity. For the nine months, patient-management revenue rose 13.6% to $185 million and network-solutions revenue rose 12.4% to $174 million. Management cited new and existing TPA customers, pharmacy services, CareIQ and group-health bill review.
- Revenue grew faster than cost of revenue in both comparison periods, improving gross margins. Management cited service-scale efficiencies. Quarterly G&A rose 12.8%, primarily from IT programming, salaries and consultants, as well as higher stock-based compensation after performance targets were met.
- Management said cash and expected internally generated funds should meet anticipated requirements for at least the next 12 months, including operations, investment and planned repurchases. It said it expected increased service levels from new TPA customers to continue in the coming year. No specific numerical earnings or revenue guidance was provided.
- Management noted seasonality from fewer working days in the fiscal third quarter. It also identified risks including declining workers’ compensation claims, competition and customer insourcing, pricing pressure, labor costs, regulatory changes, litigation, data-security or systems interruptions, and the availability of financing for growth or acquisitions.
- Routine litigation was disclosed; management did not expect its resolution to have a material financial effect. The filing reported $976,000 of unrecognized tax benefits and no impairment of goodwill, intangible assets or other long-lived assets at December 31, 2013.
Important facts for investors to verify
- Confirm the intended filing period: the document is for the quarter ended December 31, 2013, not 2012 Q3.
- Reconcile segment revenue details: the MD&A’s quarterly discussion includes amounts that appear inconsistent with quarterly totals, while its nine-month segment figures are clearly presented.
- Track whether revenue growth, improved gross margin and cash generation continue, particularly as receivables increased and capital spending rose.
- Assess the use of cash for share repurchases against investment needs, contractual obligations and the September 2014 credit-facility renewal.
- Monitor customer retention and outsourcing trends, regulatory and litigation developments, and execution and security risks associated with IT systems and the new data center.